DOI 10.1080/14796694.2025.2602198
Efficacy and safety of radiotherapy plus immunochemotherapy in patients with oligometastatic esophageal cancer.
Аннотация
BACKGROUND
This study assessed the efficacy and safety of radiotherapy (RT) plus immunochemotherapy in oligometastatic esophageal cancer (OMEC).
METHODS
A single-center retrospective study of OMEC patients who received immunochemotherapy from Jan 2019 to Jan 2022.
RESULTS
About 226 patients were included, which consisted of 108 cases in the RT plus immunochemotherapy group (iCRT), and 118 cases in the immunochemotherapy group (iCT). With a median follow-up of 22.2 months, the median progression-free survival (PFS) was 13.0 months for the iCRT group and 7.7 months for the iCT group (p < 0.001, HR = 0.520, 95%CI, 0.388-0.696). The median overall survival (OS) was 27.5 months for the iCRT group and 21.7 months for the iCT group (p = 0.026, HR = 0.670, 95%CI, 0.468-0.958). The iCRT group was associated with a higher risk of ≥grade 3 myelosuppression. No grade 5 treatment-related adverse events were observed. Univariate and multivariate analysis showed that a history of alcohol consumption, more metastatic lesions, and second-line and above treatment had inferior PFS in OMEC patients. A lower Karnofsky performance status score, more metastatic lesions, and second-line and above treatment were found to have inferior OS.
CONCLUSION
Compared to immunochemotherapy alone, RT plus immunochemotherapy showed survival benefits with manageable safety for OMEC patients.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.